TABLE 2.
Chemokine–chemokine receptor targeting agents in clinical trials
| Drug/description | Sponsors | Phase/status | Tumor type | Treatment | ClinicalTrials.govIdentifier | First received |
|---|---|---|---|---|---|---|
| CCL2‐CCR2 inhibitor | ||||||
| Carlumab/CNTO 888 (anti‐CCL2 antibody) | Centocor Research & Development | 2 a | Prostate cancer | Monotherapy | NCT00992186 | 2009‐10‐09 |
| MLN1202/S0916 (anti‐CCR2 antibody) | Southwest Oncology Group | 2 a | Metastatic cancer | Monotherapy | NCT01015560 | 2009‐11‐08 |
| Navarixin/MK‐7123/ SCH 527123(CXCR1 and CCR2 antagonist) | Merck Sharp & Dohme | 2 b | Advanced/Metastatic solid tumors | With pembrolizumab | NCT03473925 | 2018‐03‐22 |
| PF‐04136309/PF6309 (CCR2 antagonist) | Washington University School of Medicine and National Cancer Institute | 1b a | Locally advanced or borderline resectable pancreatic cancer | With FOLFIRINOX chemotherapy | NCT01413022 319 | 2011‐08‐09 |
| CCX872‐B (CCR2 antagonist) | ChemoCentryx | 1b b | Pancreatic cancer | With FOLFIRINOX chemotherapy | NCT02345408 | 2015‐01‐26 |
| AZD5069 (CCR2 antagonist) | Institute of Cancer Research, UK | 1/2 b | Metastatic castration‐resistant prostate cancer | With enzalutamide | NCT03177187 | 2017‐06‐06 |
| Reparixin (CXCR1 and CCR2 antagonist) | Dompé Farmaceutici S.p.A | 1 a | Metastatic breast cancer | With paclitaxel | NCT02001974 354 | 2013‐12‐05 |
| SX‐682(CXCR1 and CCR2 antagonist) | Syntrix Biosystems | 1 b | Metastatic melanoma | With pembrolizumab | NCT03161431 | 2017‐05‐19 |
| CCL5‐CCR5 inhibitor | ||||||
| Maraviroc/Celsentri (CCR5 antagonist) | Abramson Cancer Center of the University of Pennsylvania | 2 a | Hematologic malignancy | Monotherapy | NCT01785810 | 2013‐02‐07 |
| University Hospital Heidelberg | 1 a | Metastatic colorectal cancer | With Pembrolizumab | NCT03274804 | 2017‐09‐07 | |
| National Center for Tumor Diseases, Heidelberg | 1 a | Colorectal cancer patients with liver metastases | Monotherapy | NCT01736813 | 2012‐11‐29 | |
| Leronlimab/PRO‐140 (anti‐CCR5 antibody) | CytoDyn | 1b/2 b | Triple negative breast neoplasms | With carboplatin | NCT03838367 | 2019‐02‐12 |
| CXCL12‐CXCR4 inhibitor | ||||||
| Mogamulizumab/ KW‐0761 (anti‐CCR4 antibody) | Kyowa Kirin | 3 b | Cutaneous T‐cell lymphoma | Monotherapy | NCT01728805 355 | 2012‐11‐20 |
| European Organisation for Research and Treatment of Cancer | 2 b | Stage IB‐IIB cutaneous T‐cell lymphoma | With radiation (total skin electron beam therapy) | NCT04128072 | 2019‐10‐16 | |
| Kyowa Kirin | 2 a | Adult T‐cell leukemia‐lymphoma | Monotherapy | NCT00920790 356 | 2009‐06‐15 | |
| Kyowa Kirin | 2 a | Peripheral T/NK‐cell lymphoma | Monotherapy | NCT01192984 | 2010‐09‐01 | |
| Kyowa Kirin | 1/2 a | Advanced solid tumors | With nivolumab | NCT02705105 | 2016‐03‐10 | |
| National Cancer Institute | 1/2 b | Diffuse large B cell lymphoma | With pembrolizumab | NCT03309878 | 2017‐10‐16 | |
| Kyowa Kirin | 1 a | Non‐small cell lung cancer | With docetaxel | NCT02358473 | 2015‐02‐09 | |
| Kyowa Kirin | 1 a | Adult T‐cell leukemia‐lymphoma and peripheral T‐cell lymphoma | Monotherapy | NCT00355472 357 | 2006‐07‐24 | |
| Ulocuplumab/BMS‐936564/MDX‐1338 (Anti‐CCR4 antibody) | Bristol‐Myers Squibb | 1 a | Acute myelogenous leukemia and selected B‐cell cancers | Monotherapy | NCT01120457 | 2010‐05‐11 |
| Bristol‐Myers Squibb | 1 a | Multiple myeloma | With Revlimid/ Velcade and dexamethasone | NCT01359657 | 2011‐05‐25 | |
| AMD3100/Plerixafor (CXCR4 antagonist) | Massachusetts General Hospital | 2 b | Head and neck cancer | With pembrolizumab | NCT04058145 | 2019‐08‐15 |
| Washington University School of Medicine | 2 a | Hematologic neoplasms | With leukopheresis | NCT00914849 358 | 2009‐06‐05 | |
| Washington University School of Medicine | 1/2 a | Acute myeloid leukemia | With mitoxantrone, etoposide, and cytarabine | NCT00512252 359 | 2007‐08‐07 | |
| LY2510924 (CXCR4 antagonist) | M.D. Anderson Cancer Center | 1b a | Relapsed or refractory acute myeloid leukemia | With idarubicin and cytarabine | NCT02652871 | 2016‐01‐12 |
| Eli Lilly and Company | 2 a | Extensive stage small cell lung carcinoma | With carboplatin and etoposide | NCT01439568 360 | 2011‐09‐23 | |
| Motixafortide/BKT140/BL‐8040 (CXCR4 antagonist) | Biokine Therapeutics | 1/2a a | Multiple myeloma | Monotherapy | NCT01010880 | 2009‐11‐10 |
| M.D. Anderson Cancer Center | 2b b | Metastatic and recurrent pancreatic adenocarcinoma | With pembrolizumab | NCT02907099 | 2016‐09‐20 | |
| PTX‐9908 (CXCR4 antagonist) | TCM Biotech International Corp. | 1/2 b | Hepatocellular carcinoma | Monotherapy | NCT03812874 | 2019‐01‐23 |
| USL‐311 (CXCR4 antagonist) | Proximagen | 1/2 b | Solid tumors and relapsed/recurrent GBM | Monotherapy or with lomustine | NCT02765165 | 2016‐05‐06 |
| Balixafortide/POL6326 (CXCR4 antagonist) | Polyphor | 3 b | HER2‐ locally recurrent or metastatic breast cancer | With Eribulin | NCT03786094 | 2018‐12‐24 |
| Polyphor | 2 a | Multiple myeloma | Monotherapy | NCT01105403 | 2010‐04‐16 | |
| Polyphor | 1 a | Metastatic breast cancer | With Eribulin | NCT01837095 361 | 2013‐04‐22 | |
| GMI‐1359 (CXCR4 antagonist) | GlycoMimetics | 1b b | HR+ metastatic breast cancer | Monotherapy | NCT04197999 | 2019‐12‐13 |
| TG‐0054 (CXCR4 antagonist) | TaiGen Biotechnology | 2 a | Multiple myeloma and non‐Hodgkin lymphoma and Hodgkin disease | With G‐CSF | NCT02104427 | 2014‐04‐04 |
Source: clinicaltrials.gov.
a
Completed stage.
b
Ongoing stage, including both recruiting and nonrecruiting stages.